Search Results

Galunisertib 10 mg  | 97.09%

TargetMol

Galunisertib is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity.

More Information Supplier Page

Tozasertib 50 mg  | 99.96%

TargetMol

MK-0457 is a pan-Aurora kinase inhibitor (Kis: 0.6/18/4.6 nM for Aurora A/Aurora B/Aurora C). It shows selectivity against more than 190 different kinases.

More Information Supplier Page

Tozasertib 100 mg  | 99.96%

TargetMol

MK-0457 is a pan-Aurora kinase inhibitor (Kis: 0.6/18/4.6 nM for Aurora A/Aurora B/Aurora C). It shows selectivity against more than 190 different kinases.

More Information Supplier Page

Lenalidomide 100 mg  | 99.52%

TargetMol

Lenalidomide is a potent inhibitor of TNF-α that, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.

More Information Supplier Page

Lenalidomide 500 mg  | 99.52%

TargetMol

Lenalidomide is a potent inhibitor of TNF-α that, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.

More Information Supplier Page

Pictilisib 100 mg  | 99.22%

TargetMol

Pictilisib (GDC-0941) is a potent pan inhibitor of class I catalytic subunits of PI3K (IC50s: 3/33/3/75 nM for p110α/β/δ/γ).

More Information Supplier Page

Pictilisib 10 mg  | 99.22%

TargetMol

Pictilisib (GDC-0941) is a potent pan inhibitor of class I catalytic subunits of PI3K (IC50s: 3/33/3/75 nM for p110α/β/δ/γ).

More Information Supplier Page

Pictilisib 200 mg  | 99.22%

TargetMol

Pictilisib (GDC-0941) is a potent pan inhibitor of class I catalytic subunits of PI3K (IC50s: 3/33/3/75 nM for p110α/β/δ/γ).

More Information Supplier Page